188 related articles for article (PubMed ID: 27813087)
1. Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor.
Ciaglia E; Abate M; Laezza C; Pisanti S; Vitale M; Seneca V; Torelli G; Franceschelli S; Catapano G; Gazzerro P; Bifulco M
Int J Cancer; 2017 Feb; 140(4):959-972. PubMed ID: 27813087
[TBL] [Abstract][Full Text] [Related]
2. Recognition by natural killer cells of N6-isopentenyladenosine-treated human glioma cell lines.
Ciaglia E; Laezza C; Abate M; Pisanti S; Ranieri R; D'alessandro A; Picardi P; Gazzerro P; Bifulco M
Int J Cancer; 2018 Jan; 142(1):176-190. PubMed ID: 28884474
[TBL] [Abstract][Full Text] [Related]
3. N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux.
Ranieri R; Ciaglia E; Amodio G; Picardi P; Proto MC; Gazzerro P; Laezza C; Remondelli P; Bifulco M; Pisanti S
Cell Death Differ; 2018 Feb; 25(2):353-367. PubMed ID: 29027991
[TBL] [Abstract][Full Text] [Related]
4. N6-Isopentenyladenosine promoted HeLa cell apoptosis through inhibitions of AKT and transforming growth factor β-activated kinase 1 activation.
Li M; Qi Y; Wei J; Lu L; Zhao X; Zhou L
Tumour Biol; 2017 Mar; 39(3):1010428317695966. PubMed ID: 28345459
[TBL] [Abstract][Full Text] [Related]
5. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation.
Pisanti S; Picardi P; Ciaglia E; Margarucci L; Ronca R; Giacomini A; Malfitano AM; Casapullo A; Laezza C; Gazzerro P; Bifulco M
FASEB J; 2014 Mar; 28(3):1132-44. PubMed ID: 24265487
[TBL] [Abstract][Full Text] [Related]
7. N6-isopentenyladenosine inhibits aerobic glycolysis in glioblastoma cells by targeting PKM2 expression and activity.
Pagano C; Coppola L; Navarra G; Avilia G; Savarese B; Torelli G; Bruzzaniti S; Piemonte E; Galgani M; Laezza C; Bifulco M
FEBS Open Bio; 2024 May; 14(5):843-854. PubMed ID: 38514913
[TBL] [Abstract][Full Text] [Related]
8. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer.
Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P
J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286
[TBL] [Abstract][Full Text] [Related]
9. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
10. N6-isopentenyladenosine affects cytotoxic activity and cytokines production by IL-2 activated NK cells and exerts topical anti-inflammatory activity in mice.
Ciaglia E; Pisanti S; Picardi P; Laezza C; Sosa S; Tubaro A; Vitale M; Gazzerro P; Malfitano AM; Bifulco M
Pharmacol Res; 2014 Nov; 89():1-10. PubMed ID: 25063359
[TBL] [Abstract][Full Text] [Related]
11. The isoprenoid end product N6-isopentenyladenosine reduces inflammatory response through the inhibition of the NFκB and STAT3 pathways in cystic fibrosis cells.
Santoro A; Ciaglia E; Nicolin V; Pescatore A; Prota L; Capunzo M; Ursini MV; Nori SL; Bifulco M
Inflamm Res; 2018 Apr; 67(4):315-326. PubMed ID: 29230506
[TBL] [Abstract][Full Text] [Related]
12. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis.
Tyagi A; Agarwal R; Agarwal C
Oncogene; 2003 Mar; 22(9):1302-16. PubMed ID: 12618755
[TBL] [Abstract][Full Text] [Related]
13. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
14. The isoprenoid derivative N
Ciaglia E; Grimaldi M; Abate M; Scrima M; Rodriquez M; Laezza C; Ranieri R; Pisanti S; Ciuffreda P; Manera C; Gazzerro P; D'Ursi AM; Bifulco M
Br J Pharmacol; 2017 Jul; 174(14):2287-2301. PubMed ID: 28419419
[TBL] [Abstract][Full Text] [Related]
15. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
16. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
Yiin JJ; Hu B; Schornack PA; Sengar RS; Liu KW; Feng H; Lieberman FS; Chiou SH; Sarkaria JN; Wiener EC; Ma HI; Cheng SY
Mol Cancer Ther; 2010 Apr; 9(4):929-41. PubMed ID: 20371720
[TBL] [Abstract][Full Text] [Related]
17. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
Morgillo F; Woo JK; Kim ES; Hong WK; Lee HY
Cancer Res; 2006 Oct; 66(20):10100-11. PubMed ID: 17047074
[TBL] [Abstract][Full Text] [Related]
18. Probucol suppresses human glioma cell proliferation in vitro via ROS production and LKB1-AMPK activation.
Jiang YS; Lei JA; Feng F; Liang QM; Wang FR
Acta Pharmacol Sin; 2014 Dec; 35(12):1556-65. PubMed ID: 25399650
[TBL] [Abstract][Full Text] [Related]
19. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
[TBL] [Abstract][Full Text] [Related]
20. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]